Skip to Main Content

Paper Details

Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.
bioRxiv
8
2021
ACE2, APN01, SARS, SARS-CoV, SARS-CoV-2, VeroE6 cells, human, human lung epithelial cells, recombinant human soluble ACE2
Author NameAffiliation
Michael Murphy
Ian Crozier
Nuria MontserratInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST)
Nuria MontserratCatalan Institution for Research and Advanced Studies (ICREA)
Robert H ShoemakerNational Cancer Institute, National Institutes of Health
Robert H ShoemakerNational Cancer Institute, National Institutes of Health
  • 1 - 6

Datasets

Release 1.2